BiondVax Meets with the US Biomedical Advanced Research and Development Authority (BARDA) to Present the Use of its Universal Flu Vaccine against Global Pandemic Influenza Outbreak

Nes Ziona, Israel – February 26, 2014 – BiondVax Pharmaceuticals Ltd (TASE: BNDX), developer of a universal flu vaccine, announced today that the Company has just returned from a meeting with officials at the Biomedical Advanced Research and Development Authority/Health and Human Services (BARDA/HHS) at which clinical trial results for BiondVax’s universal flu vaccine, the Multimeric 001, was presented. BiondVax was invited to give this seminar to the Influenza Division at BARDA, during which the Company’s solution for global pandemic flu outbreaks was discussed. At the meeting the Company was informed that BARDA will consider proposals to provide pandemic vaccines and funding of clinical trials examining the usage of BiondVax’s universal flu vaccine as a primer that provides preparedness ahead of pandemic flu outbreaks. In addition, at the seminar the Company discussed the use of its vaccine as a standalone universal flu vaccine.The Influenza Division at BARDA is considered world expert on pandemic preparedness and the deliberations of national governments when evaluating medical counter measures.“The US is a key market for influenza vaccines and so it is critical to BiondVax’s success that our development strategy reflects the needs of US stakeholders, such as BARDA. The US health authorities have a major impact on the global health system and sets the agenda and the level of global preparedness for pandemic outbreaks,” comments Dr. Ron Babecoff, BiondVax’s CEO. "We continue to work in parallel with regulatory bodies and health authorities around the world to promote agreements with governments for licensing the universal flu vaccine”.